Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun. 2016;7:11375.
Couch FJ, Kuchenbaecker KB, Michailidou K et al.
Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. Int J Cancer. 2016;139(6):1303-17.
Shi J, Zhang Y, Zheng W, Michailidou K et al.
Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control. 2016;27(5):679-93.
Zhao Z, Wen W, Michailidou K et al.
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016;48(4):374-86.
Dunning AM, Michailidou K, Kuchenbaecker KB et al.
No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J Med Genet. 2016;53(5):298-309.
Easton DF, Lesueur F, Decker B et al.
Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Res. 2016;18(1):22.
Petridis C, Brook MN, Shah V et al.
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2015;108(2). pii: djv315.
Meeks HD, Song H, Michailidou K et al.
CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocr Relat Cancer. 2016;23(2):77-91.
Thompson DJ, O'Mara TA, Glubb DM et al.
Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Hum Genet. 2016;135(1):137-54.
Lei J, Rudolph A, Moysich KB et al.
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2016;141(2):386-401.
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A et al.
